* Ipsen and its partner Exelixis announce positive results from Phase 2 CABOSUN
Trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma
The post BRIEF-Ipsen and Exelixis announce positive results from Phase 2 CABOSUN trial of cabozantinib appeared first on NASDAQ.